Brief Reports
Copyright ©The Author(s) 2005.
World J Gastroenterol. Oct 7, 2005; 11(37): 5882-5887
Published online Oct 7, 2005. doi: 10.3748/wjg.v11.i37.5882
Table 1 Baseline characteristics of patients
IFN-α+lamivudine(n = 24)Lamivudine(n = 26)P
Age (median, IQR)53 (47, 60)58 (41, 66)0.36
Male (%)15/24 (63)18/26 (69)0.62
ALT, median (IQR)79 (57, 100)59 (52, 94)0.24
AST, median (IQR)59 (51, 89)60 (40, 94)0.43
log10(HBV), median (IQR)6.1 (5.2, 7.2)5.9 (5.2, 6.6)0.72
Previous IFN-α therapy (%)13/24 (54)15/26 (58)0.80
Cirrhosis1 (%)11/24 (45.8)13/26 (50)0.7